Sasmar Pharmaceuticals buys Aquatrove BioSciences
Aquatrove is focused on discovery, research and development in human reproductive health and fertility
Australian pharmaceutical firm Sasmar has bought US biotechnology company Aquatrove Biosciences, for an undisclosed sum.
Aquatrove is focused on discovery, research and development in human reproductive health and fertility.
The Brussels, Belgium-headquartered firm said the move will strengthen its global position in over-the-counter products that support health, fertility and reproduction.
Under the terms of the agreement, Sasmar has bought privately held Aquatrove, headquartered in Florida, US, in exchange for an undisclosed upfront payment in cash.
The deal captures the capability and knowhow built up over many years by the specialised team at Aquatrove
The deal, which closed this week, included Aquatrove’s global portfolio of intellectual property, patents, and ownership of research data built up over the last 14 years.
John-Michael Mancini, Sasmar’s President and CEO, said the acquisition 'captures the capability and knowhow built up over many years by the specialised team at Aquatrove' and allows the firm to realise its growth plans moving forward.
In 2008 Sasmar commercialised an Aquatrove patented formulation developed to help increase the chances of a natural pregnancy that trying-to -conceive couples could easily use, replacing regular personal lubricant with sexual intercourse during ovulation.
Data on the new formulation was presented at the 2009 Annual Meeting of the ASRM (American Society for Reproductive Medicine).
The product has since become a market leading fertility lubricant sold under the Conceive Plus Fertility Lubricant brand, the firm said.